NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Biotechnology · USD

Veradermics, Incorporated (MANE) Stock Analysis

Veradermics, Incorporated (MANE) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

MANE

$98.51

+$0.76 (+0.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MANE with… →

MANE Key Statistics

As of Sep 4, 2026
Trading
Open
$98.92
Previous Close
$97.75
Day's Range
97.20–99.89
52-Week Range
32.00–131.24
Volume
363.00K
Valuation
Market Cap
$4.12B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.51
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$70.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
41.78M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
723.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MANE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$70.00M—
2024$0.00−$26.49M—
2023$0.00−$16.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$71.56M−$70.00M—
2024$0.00—−$26.38M−$26.49M—
2023$0.00—−$17.32M−$16.49M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MANE Valuation vs Biotechnology Median

Median of 656 stocks
MetricMANEBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Veradermics, Incorporated (MANE) at $4.12B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 37.

MANE last closed at $98.51 on September 4, 2026. That is +$0.76 (+0.78%) against the previous close. Over the past 52 weeks the price has ranged from $32.00 to $131.24. The latest close sits 207.84% above that 52-week low.

Financial Health

In fiscal 2025, Veradermics, Incorporated reported revenue of $0.00. The same year closed with a net loss of $70.00M. The reported profit margin is 0%. Trailing earnings per share are −2.51.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The stored price history starts on February 4, 2026, and the total return since then is +160.95%.

Growth & Income

The record shows no dividend for MANE.

2026 is still running; the price is +160.95% year to date.

Peer Comparison

Veradermics, Incorporated (MANE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Veradermics, Incorporated MANE $4.12B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Veradermics, Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Veradermics, Incorporated

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Visit website →